Copertina

Vaccination in Multiple Myeloma: Challenges and Strategies

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	European Journal of Haematology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions
di: Santino Caserta, et al.
Pubblicazione: (2025)

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
di: Santino Caserta, et al.
Pubblicazione: (2025)

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
di: Enrica Antonia Martino, et al.
Pubblicazione: (2025)

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents
di: Ernesto Vigna, et al.
Pubblicazione: (2025)

Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions
di: Antonella Bruzzese, et al.
Pubblicazione: (2025)

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment
di: Antonella Bruzzese, et al.
Pubblicazione: (2026)

Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction
di: Enrica Antonia Martino, et al.
Pubblicazione: (2026)

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs
di: Antonella Bruzzese, et al.
Pubblicazione: (2026)

Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation
di: Antonella Bruzzese, et al.
Pubblicazione: (2026)

Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches
di: Enrica Antonia Martino, et al.
Pubblicazione: (2025)

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy
di: Santino Caserta, et al.
Pubblicazione: (2026)

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM
di: Maria Eugenia Alvaro, et al.
Pubblicazione: (2026)

First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens
di: Santino Caserta, et al.
Pubblicazione: (2026)

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management
di: Enrica Antonia Martino, et al.
Pubblicazione: (2026)

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies
di: Santino Caserta, et al.
Pubblicazione: (2026)

Avatrombopag for the Treatment of Immune Thrombocytopenia
di: Caterina Labanca, et al.
Pubblicazione: (2025)

Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies
di: Antonella Bruzzese, et al.
Pubblicazione: (2025)

Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights
di: Antonella Bruzzese, et al.
Pubblicazione: (2024)

Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia
di: Ernesto Vigna, et al.
Pubblicazione: (2025)

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy
di: Enrica Antonia Martino, et al.
Pubblicazione: (2026)

Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
di: Antonella Bruzzese, et al.
Pubblicazione: (2024)

Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives
di: Giulio Caridà, et al.
Pubblicazione: (2025)

TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions
di: Antonella Bruzzese, et al.
Pubblicazione: (2025)

Regional Standardization of CLL Management: Results of a Delphi Consensus Process
di: Enrica Antonia Martino, et al.
Pubblicazione: (2026)

Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies
di: Michael Sang Hughes, et al.
Pubblicazione: (2025)

Home‐Based Daratumumab in Patients With Multiple Myeloma
di: Tine Rosenberg, et al.
Pubblicazione: (2025)

Angiogenesis in Multiple Myeloma: 25 Years of Research in This Field
di: Domenico Ribatti
Pubblicazione: (2025)

The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma
di: Serena Barachini, et al.
Pubblicazione: (2026)

The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma
di: Anna Suska, et al.
Pubblicazione: (2025)

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
di: Shahrier Hossain, et al.
Pubblicazione: (2025)

Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients
di: Eli Zolotov, et al.
Pubblicazione: (2024)

Real‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry
di: Ludmila Muronova, et al.
Pubblicazione: (2024)

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
di: Danilo De Novellis, et al.
Pubblicazione: (2024)

Precision Anticoagulation: The Imperative Usage of DOACs for Disease‐Specific Risk Stratification in MPNs and Multiple Myeloma
di: Mehmet Baysal, et al.
Pubblicazione: (2026)

Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma
di: Bernd Metzner, et al.
Pubblicazione: (2024)

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma—A Retrospective Multicenter Analysis
di: T. Richardson, et al.
Pubblicazione: (2024)

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens
di: Emiliano Barbieri, et al.
Pubblicazione: (2026)

Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide
di: James Di Palma‐Grisi, et al.
Pubblicazione: (2026)

Outpatient Delivery of Step‐Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma
di: Aline G. Ramírez‐Alvarado, et al.
Pubblicazione: (2026)

Treatment‐Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions
di: Mays M. Jarrah, et al.
Pubblicazione: (2026)